Presentation is loading. Please wait.

Presentation is loading. Please wait.

Counts TLR3-PE 100 80 60 40 20 0 Counts TLR8-PE 100 80 60 40 20 0 Counts TLR9-PE 100 80 60 40 20 0 C AB Supplemental Figure 1.

Published byBrent Crowhurst Modified over 9 years ago

Similar presentations

Presentation on theme: "Counts TLR3-PE 100 80 60 40 20 0 Counts TLR8-PE 100 80 60 40 20 0 Counts TLR9-PE 100 80 60 40 20 0 C AB Supplemental Figure 1."— Presentation transcript:

1 Counts TLR3-PE 100 80 60 40 20 0 Counts TLR8-PE 100 80 60 40 20 0 Counts TLR9-PE 100 80 60 40 20 0 C AB Supplemental Figure 1

2 A 250 200 150 100 50 0 TLR7-PE No. of living cells (in million) B 1.5 1 0.5 0 PBS CL264 Cisplatin CL264+ Cisplatin Percentage (apoptotic cells) 50 40 30 20 10 0 PBS CL264 Cisplatin CL264+ Cisplatin Counts ** *** Supplemental Figure 2

3 6000 4000 2000 0 14000 12000 10000 8000 PBS CL264 Cisplatin(100µM)Cisplatin(200µM) Cisplatin(300µM) CL264+Cisplatin(100µM)CL264+Cisplatin(200µM) CL264+Cisplatin(300µM) ns Tumor volume (mm 3 ) ** Supplemental Figure 3

4 A B Tumor volume (mm 3 ) day 28 7500 6000 4500 3000 1500 0 CL264 Cisplatin IRS661 ODN -+-++-+ --++-++ ----+++ ++++--- - - + - Supplemental Figure 4

5 10 20 40 30 0 PBS CL264 %CD3+ cells among CD45+ cells ns PBS CL264 0 5 10 15 20 nb CD3+ cells (x10 6 ) ns PBS CL264 %CD3+ CD4+ cells among CD45+ cells 80 60 100 40 20 0 ns PBS CL264 nb CD3+ CD4+ cells (x10 6 ) 0 5 10 15 ns CD3 + T cellsCD4 + T cells PBS CL264 2 4 8 6 0 10 %CD3+ CD8+ cells among CD45+ cells ns PBS CL264 nb CD3+ CD8+ cells (x10 6 ) 0 1 2 3 ns CD8 + T cells PBS CL264 0 2 4 6 8 %CD3+ Foxp3+ cells among CD45+ cells ns nb CD3+ Foxp3+ cells (x10 6 ) PBS CL264 0 1 2 3 ns CD3 + Foxp3 + T Reg cells PBS CL264 0 5 10 15 20 %Gr1- CD11c+ cells among CD45+ cells nb Gr1- CD11c+ cells (x10 6 ) 0 5 10 15 PBS CL264 Gr1 - CD11c + dendritic cells PBS CL264 %Gr1- CD11b+ cells among CD45+ cells 0 20 40 60 PBS CL264 0 0.5 1 1.5 nb Gr1- CD11b+ cells (x10 6 ) Gr1 - CD11b + macrophages PBS CL264 10 20 40 30 %Gr1+ CD11b+ cells among CD45+ cells 0 PBS CL264 0.5 1 1.5 0 nb Gr1+ CD11b+ cells (x10 6 ) Gr1 + CD11b + MDSCs A B CD EF G ** Supplemental Figure 5

6 P value Percentage of TLR7 expressing tumor cells Supplemental Figure 6

7 P value Percentage of TLR7 expressing tumor cells Supplemental Figure 7

8 Overall Survival (OS) Time (months) 1.6.8.4 0.2 0 20 40 60 80 100 120 Responders =55/166 Non-responders =111/166 P = 0.00218 Supplemental Figure 8

9 R 2 = 0.5084 p= 0.0009 % TLR7 in tumor cells in LN after chemotherapy % TLR7 in tumor cells in lung after chemotherapy 100 80 60 40 20 0 40 6080100 0 Supplemental Figure 9

10 No Yes % TLR7 positive tumoral cells Tumor Downstaging A 100 80 60 40 20 0 B Yes 100 80 60 40 20 0 No Lymph Node Downstaging % TLR7 positive tumoral cells PatientsMean %TLR7 expressing cells P value for the mean Median %TLR7 expressing cells P value for the median Tumor downstaging Yes27 0.0053 0 0.0013 No4750 Lymph Node downstaging Yes28 0.0002 2 0.0003 No51 50 C Supplemental Figure 10

Download ppt "Counts TLR3-PE 100 80 60 40 20 0 Counts TLR8-PE 100 80 60 40 20 0 Counts TLR9-PE 100 80 60 40 20 0 C AB Supplemental Figure 1."

Similar presentations

Supplemental Figure 1 A No. at risk T3 530 483 304 185 50 T2 559 545 373 228 76 T1 540 532 375 208 64.

Supplemental Figure 1 A No. at risk T T T
Supplemental Fig 1 Rt. Lung Tumor A B Murine lung cancer model. LLC were implanted as described in Fig 1. A) Representative histology showing the distribution.

Supplemental Fig 1 Rt. Lung Tumor A B Murine lung cancer model. LLC were implanted as described in Fig 1. A) Representative histology showing the distribution.
Supplemental Table 1 Source and authentication of cell lines.

Supplemental Table 1 Source and authentication of cell lines.
Supplemental Digital Content Figure 1A A Academic/Research Program Extent of Lung Resection No. of SubjectEventCensored Median Survival (95% CI)60 mo Survival.

Supplemental Digital Content Figure 1A A Academic/Research Program Extent of Lung Resection No. of SubjectEventCensored Median Survival (95% CI)60 mo Survival.
Supplemental Figure 1. Loss of Stat3 expression did not change IFN-induced chemokine levels in tumors. (A) Realtime PCR analysis of mRNA expression levels.

Supplemental Figure 1. Loss of Stat3 expression did not change IFN-induced chemokine levels in tumors. (A) Realtime PCR analysis of mRNA expression levels.
Supplementary Figures NormalCRC CRC+5FU CRC+CPT11 100µm S1.

Supplementary Figures NormalCRC CRC+5FU CRC+CPT11 100µm S1.
Supplementary Figure 1: Correlation analysis of DKC1 mRNA and dyskerin protein quantity in neuroblastoma cell lines.

Supplementary Figure 1: Correlation analysis of DKC1 mRNA and dyskerin protein quantity in neuroblastoma cell lines.
Shimura Supplemental Figure 1

Shimura Supplemental Figure 1
Reduced Level of CD44 and Hyaluronan Associated with Unfavorable Prognosis in Clinical Stage I Cutaneous Melanoma  Jari M. Karjalainen, Raija H. Tammi,

Reduced Level of CD44 and Hyaluronan Associated with Unfavorable Prognosis in Clinical Stage I Cutaneous Melanoma  Jari M. Karjalainen, Raija H. Tammi,
Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.

Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.
Lung squamous cell carcinoma

Lung squamous cell carcinoma
Volume 110, Issue 6, Pages (December 1996)

Volume 110, Issue 6, Pages (December 1996)
Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations 

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations 
Foxp3+ Regulatory T Cells and Natural Killer Cells Distinctly Infiltrate Primary Tumors and Draining Lymph Nodes in Pulmonary Adenocarcinoma  Thomas Schneider,

Foxp3+ Regulatory T Cells and Natural Killer Cells Distinctly Infiltrate Primary Tumors and Draining Lymph Nodes in Pulmonary Adenocarcinoma  Thomas Schneider,
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Volume 131, Issue 4, Pages (April 2007)

Volume 131, Issue 4, Pages (April 2007)
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
Baseline tumor biopsies

Baseline tumor biopsies
The beauty of TLR agonists for CTCL

The beauty of TLR agonists for CTCL
Skin-draining lymph nodes contain dermis-derived CD103− dendritic cells that constitutively produce retinoic acid and induce Foxp3+ regulatory T cells.

Skin-draining lymph nodes contain dermis-derived CD103− dendritic cells that constitutively produce retinoic acid and induce Foxp3+ regulatory T cells.

Similar presentations

Ads by Google